Payment overview · 2025
General Payments
$862.11
39 reported records · 9 companies
Healthcare provider profile · identity verified
Rhoniel Perdigon, MD
Allopathic & Osteopathic Physicians|Family Medicine · ENGLEWOOD, FL · NPI 1386657393
Verified facts
What the public records show
CMS Open Payments records show Rhoniel Perdigon, MD received $862.11 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid, Qulipta, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $290.35 | 33.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $234.63 | 27.2% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $225.20 | 26.1% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.91 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.07 | 2.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.65 | 2.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.80 | 1.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.41 | 1.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.09 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $862.11 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $241.10 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $179.08 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $167.87 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $165.35 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $136.63 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $131.78 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.55 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.94 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 782 | 223 |
| Lisinopril | Lisinopril | 551 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 129 |
| Alprazolam | Alprazolam | 454 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 123 |
| Omeprazole | Omeprazole | 376 | 111 |
| Trazodone Hcl | Trazodone Hcl | 324 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 303 | 94 |
| Tramadol Hcl | Tramadol Hcl | 301 | 84 |
| Losartan Potassium | Losartan Potassium | 285 | 83 |
| Simvastatin | Simvastatin | 276 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 231 | 65 |
| Gabapentin | Gabapentin | 221 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 56 |
| Allopurinol | Allopurinol | 175 | 51 |
| Metformin Hcl Er | Metformin Hcl | 161 | 35 |
| Montelukast Sodium | Montelukast Sodium | 161 | 53 |
| Clonazepam | Clonazepam | 156 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 44 |
| Meloxicam | Meloxicam | 130 | 43 |
| Famotidine | Famotidine | 119 | 36 |
| Eliquis | Apixaban | 118 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 24 |
| Atenolol | Atenolol | 112 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 112 | 40 |
| Metformin Hcl | Metformin Hcl | 111 | 35 |
| Sertraline Hcl | Sertraline Hcl | 111 | 31 |
| Prednisone | Prednisone | 108 | 76 |
| Furosemide | Furosemide | 107 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 103 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 31 |
| Bupropion Xl | Bupropion Hcl | 98 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 31 |
| Ezetimibe | Ezetimibe | 92 | 31 |
| Synthroid | Levothyroxine Sodium | 90 | 24 |
| Potassium Chloride | Potassium Chloride | 86 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 21 |
| Temazepam | Temazepam | 85 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 23 |
| Finasteride | Finasteride | 82 | 23 |
| Lorazepam | Lorazepam | 80 | 26 |
| Alendronate Sodium | Alendronate Sodium | 77 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 21 |
| Glimepiride | Glimepiride | 69 | 21 |
| Mirtazapine | Mirtazapine | 69 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 19 |
| Carvedilol | Carvedilol | 63 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 16 |
| Buspirone Hcl | Buspirone Hcl | 60 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 15 |
| Donepezil Hcl | Donepezil Hcl | 56 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 55 | 17 |
| Fenofibrate | Fenofibrate | 53 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Diazepam | Diazepam | 52 | suppressed |
| Ozempic | Semaglutide | 52 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 41 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 19 |
| Xarelto | Rivaroxaban | 42 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 15 |
| Clonidine Hcl | Clonidine Hcl | 38 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Jardiance | Empagliflozin | 37 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 13 |
| Valsartan | Valsartan | 35 | 11 |
| Acyclovir | Acyclovir | 34 | 14 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 13 |
| Mupirocin | Mupirocin | 18 | 13 |
| Felodipine Er | Felodipine | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Irbesartan | Irbesartan | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Xanax | Alprazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $862.11 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, EVENITY, GEMTESA, OTEZLA, Ozempic, PAXLOVID, QULIPTA, REPATHA, Rybelsus, UBRELVY, VOQUEZNA, WATCHMAN FLX, Wegovy, ZENPEP | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error